Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic.
Level 4 - case-series / case-control
Case reports and clinical subtype classification without controlled comparison
PubMed 26870879 · doi:10.18632/aging.100896
What was done
The author presents a clinical categorization framework focusing on type 3 (cortical) Alzheimer's disease, proposing that it is caused by exposure to specific environmental toxins and manifests as an inhalational Alzheimer's disease (IAD) linked to chronic inflammatory response syndrome (CIRS).
What was found
The abstract provides no quantitative data, sample sizes, or statistical metrics. It asserts that type 3 Alzheimer's disease is predominantly inhalational and related to biotoxin exposures such as mycotoxins.
Why it matters
It hypothesizes an environmental and potentially treatable etiology for a subset of patients presenting with cognitive decline and cortical Alzheimer's features.
Limits
The abstract reports no empirical data, sample size, control group, or standardized diagnostic criteria for inhalational Alzheimer's disease. The causal relationship between biotoxin exposure and Alzheimer's pathology remains unverified in this report.
Cited by
- context In Alzheimer's subtype classification, purely toxic (type 3) represents 15 to 20 percent of cases, but 60 to 70 percent of patients show some degree of type 3 toxin or pathogen exposure.